Literature DB >> 31009805

Metaproteomics of fecal samples of Crohn's disease and Ulcerative Colitis.

T Lehmann1, K Schallert2, R Vilchez-Vargas3, D Benndorf4, S Püttker5, S Sydor6, C Schulz7, L Bechmann8, A Canbay9, B Heidrich10, U Reichl11, A Link12, R Heyer13.   

Abstract

Crohn's Disease (CD) and Ulcerative Colitis (UC) are chronic inflammatory bowel diseases (IBD) of the gastrointestinal tract. This study used non-invasive LC-MS/MS to find disease specific microbial and human proteins which might be used later for an easier diagnosis. Therefore, 17 healthy controls, 11 CD patients and 14 UC patients but also 13 Irritable Bowel Disease (IBS) patients, 8 Colon Adenoma (CA) patients, and 8 Gastric Carcinoma (GCA) patients were investigated. The proteins were extracted from the fecal samples with liquid phenol in a ball mill. Subsequently, the proteins were digested tryptically to peptides and analyzed by an Orbitrap LC-MS/MS. For protein identification and interpretation of taxonomic and functional results, the MetaProteomeAnalyzer software was used. Cluster analysis and non-parametric test (analysis of similarities) separated healthy controls from patients with CD and UC as well as from patients with GCA. Among others, CD and UC correlated with an increase of neutrophil extracellular traps and immune globulins G (IgG). In addition, a decrease of human IgA and the transcriptional regulatory protein RprY from Bacillus fragilis was found for CD and UC. A specific marker in feces for CD was an increased amount of the human enzyme sucrose-isomaltase. SIGNIFICANCE: Crohn's Disease and Ulcerative Colitis are chronic inflammatory diseases of the gastrointestinal tract, whose diagnosis required comprehensive medical examinations including colonoscopy. The impact of the microbial communities in the gut on the pathogenesis of these diseases is poorly understood. Therefore, this study investigated the impact of gut microbiome on these diseases by a metaproteome approach, revealing several disease specific marker proteins. Overall, this indicated that fecal metaproteomics has the potential to be useful as non-invasive tool for a better and easier diagnosis of both diseases.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Crohn's Disease; Fecal samples; Gastrointestinal tract; Inflammatory Bowel Disease; Metaproteomics; Non-invasive diagnosis; Ulcerative Colitis

Year:  2019        PMID: 31009805     DOI: 10.1016/j.jprot.2019.04.009

Source DB:  PubMed          Journal:  J Proteomics        ISSN: 1874-3919            Impact factor:   4.044


  10 in total

Review 1.  The emerging role of neutrophilic extracellular traps in intestinal disease.

Authors:  Feng Chen; Yongqiang Liu; Yajing Shi; Jianmin Zhang; Xin Liu; Zhenzhen Liu; Jipeng Lv; Yufang Leng
Journal:  Gut Pathog       Date:  2022-06-22       Impact factor: 5.324

Review 2.  Metaproteomic analysis of human gut microbiome in digestive and metabolic diseases.

Authors:  Sheng Pan; Ru Chen
Journal:  Adv Clin Chem       Date:  2020-02-17       Impact factor: 6.303

Review 3.  Multi-Omics Analysis of Gut Microbiota in Inflammatory Bowel Diseases: What Benefits for Diagnostic, Prognostic and Therapeutic Tools?

Authors:  Vickie Lacroix; Alexis Cassard; Emmanuel Mas; Frederick Barreau
Journal:  Int J Mol Sci       Date:  2021-10-19       Impact factor: 5.923

4.  Metaproteomics as a tool for studying the protein landscape of human-gut bacterial species.

Authors:  Moses Stamboulian; Jamie Canderan; Yuzhen Ye
Journal:  PLoS Comput Biol       Date:  2022-03-18       Impact factor: 4.779

5.  Modern Metaproteomics: A Unique Tool to Characterize the Active Microbiome in Health and Diseases, and Pave the Road towards New Biomarkers-Example of Crohn's Disease and Ulcerative Colitis Flare-Ups.

Authors:  Céline Henry; Ariane Bassignani; Magali Berland; Olivier Langella; Harry Sokol; Catherine Juste
Journal:  Cells       Date:  2022-04-14       Impact factor: 7.666

6.  Discovering Biomarkers for Non-Alcoholic Steatohepatitis Patients with and without Hepatocellular Carcinoma Using Fecal Metaproteomics.

Authors:  Svenja Sydor; Christian Dandyk; Johannes Schwerdt; Paul Manka; Dirk Benndorf; Theresa Lehmann; Kay Schallert; Maximilian Wolf; Udo Reichl; Ali Canbay; Lars P Bechmann; Robert Heyer
Journal:  Int J Mol Sci       Date:  2022-08-09       Impact factor: 6.208

7.  Fecal Metaproteomics Reveals Reduced Gut Inflammation and Changed Microbial Metabolism Following Lifestyle-Induced Weight Loss.

Authors:  Ronald Biemann; Enrico Buß; Dirk Benndorf; Theresa Lehmann; Kay Schallert; Sebastian Püttker; Udo Reichl; Berend Isermann; Jochen G Schneider; Gunter Saake; Robert Heyer
Journal:  Biomolecules       Date:  2021-05-12

8.  Distinct Human Gut Microbial Taxonomic Signatures Uncovered With Different Sample Processing and Microbial Cell Disruption Methods for Metaproteomic Analysis.

Authors:  Carmen García-Durán; Raquel Martínez-López; Inés Zapico; Enrique Pérez; Eduardo Romeu; Javier Arroyo; María Luisa Hernáez; Aida Pitarch; Lucía Monteoliva; Concha Gil
Journal:  Front Microbiol       Date:  2021-07-05       Impact factor: 5.640

9.  Neutrophil Extracellular Trap Density Increases With Increasing Histopathological Severity of Crohn's Disease.

Authors:  Angie L Schroder; Belal Chami; Yuyang Liu; Chloe M Doyle; Mary El Kazzi; Golo Ahlenstiel; Gulfam Ahmad; Nimalan Pathma-Nathan; Geoff Collins; James Toh; Andrew Harman; Scott Byrne; Grahame Ctercteko; Paul K Witting
Journal:  Inflamm Bowel Dis       Date:  2022-03-30       Impact factor: 7.290

10.  In Silico Evaluation of Putative S100B Interacting Proteins in Healthy and IBD Gut Microbiota.

Authors:  Massimiliano Orsini; Rosa Di Liddo; Federica Valeriani; Marzia Mancin; Renata D'Incà; Andrea Castagnetti; Antonio Aceti; Pier Paolo Parnigotto; Vincenzo Romano Spica; Fabrizio Michetti
Journal:  Cells       Date:  2020-07-15       Impact factor: 6.600

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.